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Summary  In  2009,  a  novel  inﬂuenza  A  (H1N1)  virus  emerged  and  rapidly  spread
around  the  world,  leading  to  a  pandemic.  In  contrast  to  the  high  rate  of  primaryReinfection infection,  reinfection  with  inﬂuenza  A  (H1N1)  2009  is  rather  rare.  In  this  report,
we  describe  a  case  of  inﬂuenza  A  (H1N1)  2009  reinfection  that  occurred  within  an
interval  of  5  months  in  Thailand.
©  2012  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Ltd.  All  rights  reserved.
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n  April  2009,  a  novel  inﬂuenza  A  (H1N1)  virus
merged and  rapidly  spread  across  North  America
1]. This  novel  virus  is  genetically  distinct  because
t derives  genes  segments  from  both  North  Ameri-
an and  Eurasian  swine  inﬂuenza  virus  lineages  [2].
herefore,  the  worldwide  population  was  highly
usceptible  to  infection  with  this  novel  virus.  It
ook less  than  3 months  after  the  identiﬁcation  of
he ﬁrst  case  for  the  H1N1  pandemic  to  occur.  In
ontrast  to  the  high  rate  of  primary  infection,  rein-
ection with  H1N1  is  rather  rare.
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oi:10.1016/j.jiph.2011.10.010In  Thailand,  the  ﬁrst  cases  inﬂuenza  A (H1N1)
ere reported  in  May  of  2009  [3],  and  these  initial
ases were  followed  shortly  thereafter  by  a major
utbreak.  The  Department  of  Disease  Control,  part
f the  Thai  Ministry  of  Public  Health,  reported  that
he ﬁrst  outbreak  lasted  for  6  months  (May—October
009) and  that  the  average  rate  of  infection  in  the
hai population  was  13%  (about  8.4  million  people)
3].
In this  report,  we  describe  a  case  of  inﬂuenza  A
H1N1) 2009  reinfection  in  Thailand.
ase reportn  July  2009,  a  39-year-old  Thai  woman,  who  was
ed-ridden  due  to  cerebral  palsy  and  epilepsy,
resented to  the  emergency  room  (ER)  at  the
 Sciences. Published by Elsevier Ltd. All rights reserved.
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Faculty  of  Medicine,  Ramathibodi  Hospital,
Bangkok, Thailand,  with  a  fever,  drowsiness,  and
a generalized  tonic—clonic  seizure.  Six  days  prior
to admission,  she  had  a  low-grade  fever  and  a
productive  cough.  The  patient  initially  received
oral co-amoxiclav.  However,  her  clinical  condition
continued  to  deteriorate.  Three  to  four  days  prior
to admission,  a  high-grade  fever  and  a  more  pro-
ductive  cough  producing  more  sputum  were  noted.
A few  hours  prior  to  presenting  to  the  hospital,
a generalized  tonic—clonic  seizure  occurred  for
a brief  period  of  time.  Upon  arrival,  a  physical
examination revealed  a  temperature  of  37.6 ◦C,  a
blood pressure  of  106/86  mm  Hg,  a respiratory  rate
of 22  breaths  per  minute  and  a  pulse  rate  of  101
beats per  minute.  Her  maximum  body  temperature
was 38.5 ◦C.  A  lung  examination  revealed  bilateral
rhonchi. The  exam  was  otherwise  unremarkable.
Her room  air  oxygen  saturation  was  92%.  Chest
radiography showed  increased  interstitial  inﬁltra-
tion at  the  left  peri-hilar  area  of  the  left  lower
lobe. A  complete  blood  count  revealed  that  her
hemoglobin  was  11.3  g/dL;  her  hematocrit  was
34.9%;  her  white  blood  cell  count  was  7650/mm3
with  neutrophils  at  51%,  lymphocytes  at  26%,
monocytes at  22%,  and  basophils  at  1%;  and  her
platelets  were  274,000/mm3.
The patient  was  admitted  to  the  hospital.  A  nasal
swab was  tested  for  inﬂuenza  virus  by  real-time
polymerase chain  reaction  (PCR).  The  detection  of
inﬂuenza virus  was  carried  out  by  the  extraction
of viral  RNA  using  the  NucliSens  easyMAG  plat-
form for  total  nucleic  acid  extraction  (bioMérieux,
France) by  the  off-board  protocol  according  to
the manufacturer’s  instructions.  Real-time  reverse-
transcriptase  PCR  (RT-PCR)  for  the  detection  of
inﬂuenza  A  (H1N1)  2009  was  conducted  using
the LightCycler  480  instrument  (Roche  Diagnostics
GmbH, Germany)  and  the  U.S.  FDA  approved  Real-
Time ready  Inﬂuenza  A  (H1N1)  Detection  Set  (Roche
Biochemical;  Cat.  No.  05  640  393  001),  according  to
the manufacturer’s  instructions.  This  real-time  PCR
test was  positive  for  inﬂuenza  A  (H1N1)  2009.  The
patient received  treatment  with  oral  oseltamivir
at 75  mg  twice  daily  for  5  days.  Clinical  improve-
ment was  noted  after  6  days  in  the  hospital.  After
10 days  of  hospitalization,  follow-up  chest  radio-
graphy  showed  resolution  of  the  recently  noted
pulmonary inﬁltration.
In  December  2009,  approximately  5  months  after
her primary  infection  with  the  novel  2009  virus,
this same  patient  presented  to  the  emergency  room
with a  displaced  gastrostomy  tube.  In  addition,
she had  symptoms  associated  with  a  respiratory
tract infection  that  were  noted  by  her  fam-
ily members.  She  had  a  productive  cough  that
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roduced  white  sputum,  rhinorhea  and  tachyp-
ea without  a fever.  On  examination,  her  body
emperature  was  37.2 ◦C,  her  blood  pressure  was
1/62 mmHg,  her  respiratory  rate  was  22  breaths
er minute,  and  her  pulse  rate  was  97  beats
er minute.  An  oral  examination  was  normal,
nd the  lungs  were  clear.  Chest  radiography  was
ot performed.  A  nasal  swab  was  collected  and
ested by  real-time  PCR  for  inﬂuenza  virus,  and
his swab  was  determined  to  be  positive  for
nﬂuenza A  (H1N1)  2009.  To  conﬁrm  the  presence
f inﬂuenza  A  (H1N1)  2009,  pyrosequence  analysis
as performed.  RT-PCR  ampliﬁcations  were  per-
ormed using  the  OneStep  RT-PCR  system  (Qiagen,
ermany).  Primers  were  used  at  20  M  in  a  standard
5 l  reaction  mixture,  and  the  ampliﬁcation  was
erformed  for  45  cycles.  Pyrosequencing  was  per-
ormed using  Pyro  Gold  reagents  (Qiagen,  GmbH,
ermany)  according  to  manufacturer’s  recommen-
ations. The  accuracy  of  the  matrix  protein  2,
euraminidase,  and  hemagglutinin  gene  sequences
f inﬂuenza  A  (H1N1)  2009  obtained  via  pyrose-
uencing were  conﬁrmed  by  comparison  of  the
esults  with  the  sequences  that  were  determined
y conventional  sequencing.  The  results  from  the
yrosequence  analysis  conﬁrmed  the  presence  of
nﬂuenza  A  (H1N1)  2009.  The  patient  received  a  5-
ay course  of  a  standard  dose  of  oral  oseltamivir.
o respiratory  complications  were  noted  during  the
reatment.
In this  report,  we  describe  a case  of  inﬂuenza  A
H1N1) 2009  reinfection  that  occurred  in  a  patient
ho had  no  known  underlying  immunological  dis-
ase. Although  the  reinfection  rate  is  extremely
ow, cases  of  inﬂuenza  A  (H1N1)  2009  reinfection
ave recently  been  reported  [4].  A  recent  report
ndicated that  reinfection  occurred  in  patients
ho remained  in  an  environmental  exposure  area
nd during  the  grey  zone  when  the  immunological
esponse has  not  had  enough  time  to  fully  develop.
owever, for  our  case,  the  interval  between  the  pri-
ary and  secondary  infections  was  approximately
 months.  During  the  primary  infection,  our  patient
eveloped  more  a  severe  infection.  She  was  diag-
osed with  inﬂuenza  A  (H1N1)  2009  pneumonia,  and
 high  viral  load  was  documented  by  real-time  PCR
nalysis,  which  demonstrated  an  extremely  high
mplitude  for  the  melting  curve  (Fig.  1).  During
he second  infection,  her  illness  was  milder.  The
atient only  experienced  symptoms  of  an  upper
espiratory  tract  infection.  Moreover,  the  real-time
CR analysis  also  suggested  a  lower  viral  load
Fig. 1).  We  hypothesize  that  this  patient  had  sub-
ptimal immune  protection  from  the  ﬁrst  natural
nfection.  Our  pyrosequence  analysis  showed  that
here were  no  changes  in  the  amino  acid  sequence
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Figure  1  Ampliﬁcation  curves  for  real-time  RT-PCR  primers  and  hydrolysis  probes  for  the  detection  of  the  inﬂuenza
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o  suggest  antigenic  drift  of  the  virus  prior  to
er second  infection.  In  our  virology  laboratory,
e do  not  perform  antiviral  susceptibility  tests.
ased  on  general  knowledge,  the  humoral  immune
esponse  against  inﬂuenza  virus  is  essential  to  pre-
ent infection  and  reinfection  of  the  host.  Survivors
rom  the  1918  inﬂuenza  pandemic  possessed  highly
unctional  neutralizing  antibodies  to  the  virus  and
ustainable  circulating  B  memory  cells  for  many
ecades  after  exposure  [5].  The  basic  mechanisms
or a  decrease  in  the  antibody-response  to  inﬂuenza
irus  may  include  a  host  immunological  defect,
uch as  an  impaired  function  or  deﬁciency  of  a
emory  B-cell,  immune  senescence  or  antigenic
ifferences in  inﬂuenza  virus  strains  that  could
otentially escape  the  host’s  pre-existing  neutraliz-
ng antibodies.  Experimental  studies  have  recently
hown  that  viral  factors  might  also  play  a  signiﬁ-
ant role.  The  immune  evasion  of  inﬂuenza  A  virus
y the  expression  of  non-structural  protein  1  may
imit or  delay  the  innate  immune  response,  and
his delay  would  likely  contribute  to  the  inabil-
ty of  the  host  to  prime  the  adaptive  immune
esponse following  infection  [6].  For  the  inﬂuenza  A
H1N1) 2009  virus,  the  patterns  of  innate  and  adap-
ive immune  responses  in  humans  have  not  been
ell described  [7].  A  study  on  the  human  immune
esponse  demonstrated  signiﬁcantly  lower  numbers
t
n
tt  and  second  infections  with  inﬂuenza  A  (H1N1)  2009  in
f  CD4  lymphocytes  and  B  lymphocytes  in  patients
nfected  with  inﬂuenza  A  (H1N1)  2009  [8].  How-
ver, the  decreased  number  of  B  lymphocytes  was
ransient.  Recently,  a study  of  neutralizing  anti-
ody titer  (NAT)  against  inﬂuenza  A  (H1N1)  2009
irus in  convalescent  patients  showed  that  approx-
mately  10%  of  these  patients  do  not  generate
eroprotective  NAT  [9].  This  study  did  mention  that
ntiviral therapy  may  not  contribute  to  the  lower
AT and  might  not  be  associated  with  the  higher
einfection  rate.  To  date,  there  are  limited  data
o suggest  that  antiviral  drugs  have  the  signiﬁ-
ant impact  on  the  patients’  immune  responses.
herefore, these  ﬁndings  may  partially  support  our
ypothesis  that  the  patient’s  sub-optimal  immune
esponse  following  the  primary  infection  failed  to
enerate a protective  response  that  would  have
revented  reinfection  in  this  patient.  However,  the
everity of  the  infection  may  have  been  limited  by
he patient’s  immunity  status.
In this  case  study,  we  showed  that  inﬂuenza
 (H1N1)  2009  reinfection  is  possible;  however,
he severity  of  disease  was  signiﬁcantly  lower
pon reinfection.  Our  ﬁnding  suggests  the  possibil-
ty of  a  sub-optimal  immune  response  that  failed
o provide  protection  after  exposure  to  the  ﬁrst
atural  infection.  Further  study  is  necessary  to  bet-
er understand  the  nature  of  the  host’s  immune
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response  to  inﬂuenza  A  (H1N1)  2009  virus  infec-
tion and  to  elucidate  the  mechanisms  that  lead  to
immunological  defects  associated  with  reinfection
to identify  patients  at  risk  for  reinfection.
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